Compare Incyte Corporation (INCY) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NetApp Inc. — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while NetApp Inc. trades at $164.23 (market cap $31.57B). The key difference: NetApp Inc. is the larger of the two by market cap, and NetApp Inc. pays a 1.29% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NTAP | |
|---|---|---|
Market Cap | $23.11B | $31.57B |
Sector | Health | Technology |
52-Week High | $118.52 | $181.08 |
52-Week Low | $67.38 | $94.11 |
Enterprise Value | $19.13B | $30.72B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
NetApp (NTAP) trades at $161.16, down 1.66% on the day, near its pivot point of $164. The stock exhibits a bullish technical trend with strong moving average signals. Fundamentally, the company shows robust profitability with a net income margin of 18.43% and has beaten earnings estimates for three consecutive quarters. Recent strategic moves include the acquisition of DataPelago to bolster AI data infrastructure capabilities, signaling growth focus.
The outlook for NTAP is positive, driven by AI-driven demand and consistent earnings outperformance, though risks include competitive pressures and reliance on enterprise spending. Analyst consensus leans bullish with a price target of $167.45, offering modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
